Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A Jonas, MD PhD, Aaron C. Logan, MDPhDMPhil, Deepa Jeyakumar, MD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Matthew J. Wieduwilt, Leslie G. Oesterich, MD, Peter T. Curtin, MD

Blood (2017) 130 (Supplement 1): 2973.

https://doi.org/10.1182/blood.V130.Suppl_1.2973.2973

Published: 2017

Journal Articles

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Rita Assi, MD, Prithviraj Bose, MD, Srdan Verstovsek, MD PhD, Yvonne Gasior, RN, Nitin Jain, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MDMSc, Naveen Pemmaraju, MD, Steven Kornblau, MD, Tapan Kadia, MD, Naval Daver, MD, Mark Brandt, BS, Sherry Pierce, BSN, BA, Xuelin Huang, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS

Blood (2017) 130 (Supplement 1): 1379.

https://doi.org/10.1182/blood.V130.Suppl_1.1379.1379

Published: 2017

Journal Articles

Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study

Christophe Bonnet, MD PhD, Thierry Lamy, MD PhD, Christophe Fruchart, MD, Steven Le Gouill, MD PhD, Katharina Gunzer, MD, Thomas Gastinne, MD, Fabrice Jardin, MD PhD, Lionel Karlin, MD, Roch Houot, MD PhD, Jehan Dupuis, MD, Hervé Tilly, MD PhD, Gilles A. Salles

Blood (2016) 128 (22): 5384.

https://doi.org/10.1182/blood.V128.22.5384.5384

Published: 2016

Journal Articles

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Prithviraj Bose, MD, Srdan Verstovsek, MD PhD, Yvonne Gasior, Nitin Jain, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Steven M. Kornblau, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Mark Brandt, BS, Sherry Pierce, BSN, BA, Graciela M. Nogueras-Gonzalez, Xuelin Huang, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2016) 128 (22): 4262.

https://doi.org/10.1182/blood.V128.22.4262.4262

Published: 2016

Journal Articles

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

Jatin Shah, Ruben Niesvizky, MD, Edward Stadtmauer, Robert M. Rifkin, James Berenson, MD, Jesus G. Berdeja, MD, Jeff P. Sharman, MD, Roger Lyons, Zandra Klippel, MD, Hansen Wong, Yu-Lin Chang, Saad Usmani

Blood (2015) 126 (23): 378.

https://doi.org/10.1182/blood.V126.23.378.378

Published: 2015

Journal Articles

Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation

Brenda M. Sandmaier, MD, Samer K Khaled, MD, Betul Oran, MD, Guy Gammon, MD, Denise Trone, Olga Frankfurt, MD

Blood (2014) 124 (21): 428.

https://doi.org/10.1182/blood.V124.21.428.428

Published: 2014

Journal Articles

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Nancy L. Bartlett, MD, Betsy R. LaPlant, MS, Jing Qi, MD PhD, Stephen M. Ansell, MD PhD, John G. Kuruvilla, MD, Craig B. Reeder, MD, Lim S. Thye, MD, Daniel M. Anderson, MD MPH, Charles Erlichman, MD, Barry A. Siegel, MD

Blood (2014) 124 (21): 800.

https://doi.org/10.1182/blood.V124.21.800.800

Published: 2014

Journal Articles

Inducing Iron Deficiency Dramatically Improves Erythropoiesis and Photosensitivity In Congenital Erythropoietic Porphyria (CEP)

Daniel N. Egan, MD, Zhantao Yang, MD, John Phillips, PhD, Janis L. Abkowitz, MD

Blood (2013) 122 (21): 3442.

https://doi.org/10.1182/blood.V122.21.3442.3442

Published: 2013

Journal Articles

Post-Marketing Safety Experience with Edoxaban in Japan for Thromboprophylaxis Following Major Orthopedic Surgery

Yasufumi Kuroda, PhD, Hitoshi Hotoda, PhD, Yasuhiro Nishikawa, MD, Akinori Nishiwaki, PhD

Blood (2012) 120 (21): 4697.

https://doi.org/10.1182/blood.V120.21.4697.4697

Published: 2012

Journal Articles

RCHOP Therapy Overcome Gastric Diffuse Large B Cell Lymphoma without Surgery

Yuko Mishima, MD, Yasuhito Terui, MD, PhD, Masahiro Yokoyama, MD, Sakura Sakajiri, MD, PhD, Noriko Nishimura, MD, PhD, Kenji Nakano, MD, Eriko Nara, MD, Kazuhito Suzuki, MD, Kentaro Nasu, MD, Shunji Takahashi, MD, PhD, Kengo Takeuchi, MD, PhD, Kiyohiko Hatake, MD, PhD

Blood (2010) 116 (21): 1760.

https://doi.org/10.1182/blood.V116.21.1760.1760

Published: 2010

Journal Articles

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

Guillaume Cartron, MD, PhD, Catherine Thieblemont, MD, PhD, Philippe Solal-Celigny, MD, Franck Morschhhauser, MD, PhD, Corinne Haioun, MD, Reda Bouabdallah, MD, Thierry Lamy, MD, PhD, Noel Milpied, MD, Steven Le Gouill, MD, Pierre Feugier, MD, PhD, Joe Birkett, PhD, Michael K. Wenger, MD, Elina Asikanius, Gilles Salles

Blood (2010) 116 (21): 2878.

https://doi.org/10.1182/blood.V116.21.2878.2878

Published: 2010

Journal Articles

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Blood (2008) 112 (11): 2776.

https://doi.org/10.1182/blood.V112.11.2776.2776

Published: 2008

Journal Articles

Purging in Vivo and Auto-Transplantation in Patients with Poor Prognosis Lymphoproliferative Disease

Vincenzo Mettivier, Luca Pezzullo, Olimpia Finizio, Lucia Bene, Stefano Rocco, Pellegrino Musto, MD, Giuseppe Nunziata, Laura Mettivier

Blood (2008) 112 (11): 4446.

https://doi.org/10.1182/blood.V112.11.4446.4446

Published: 2008

Journal Articles

Cost Estimates of Managing Grade III and IV Pleural Effusions, Pericardial Effusions, and Non-Variceal Gastrointestinal Hemorrhages in Cancer Patients.

Grant H. Skrepnek, PhD, Jeana L. Skora, PharmD

Blood (2006) 108 (11): 5510.

https://doi.org/10.1182/blood.V108.11.5510.5510

Published: 2006

Journal Articles

Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus Thalidomide in Refractory Myeloma.

Stefania Ciolli, MD, Franco Leoni, md, Cinzia Casini, md, Carla Breschi, md, Alberto Bosi, phd

Blood (2006) 108 (11): 5087.

https://doi.org/10.1182/blood.V108.11.5087.5087

Published: 2006

Journal Articles

Surgical Complications in Patients Treated with Chemotherapy for Gastric Diffuse Large B Cell Lymphoma.

Galia Spectre, MD, Diana Libster, MD, Sigal Grisariu, MD, Nael Da’as, MD, Zvi Gimmon, MD, Ora Paltiel, MDCM

Blood (2005) 106 (11): 4732.

https://doi.org/10.1182/blood.V106.11.4732.4732

Published: 2005

Journal Articles

Anti-Thrombotic Action of DZ-697b, a Novel Anti-Platelet Agent, on Photochemically Induced Thrombosis with Lower Bleeding Risk in Guinea Pigs.

Tomoko Shibutani, PhD, Takako Iijima, Yuki Kaneda, Sumie Muramatsu, Yoshiyasu Ogihara, PhD, Toshiro Shibano, PhD

Blood (2005) 106 (11): 1870.

https://doi.org/10.1182/blood.V106.11.1870.1870

Published: 2005

Journal Articles

Rituximab - Inmunotherapy Combined with Chemotherapy, CHOP for the Treatment of Patients with Difusse Large B - Cell Lymphoma (DLBCL).

Jorge H. Milone, MD, Fernando Bezares, MD, Maria del Carmen Ardaiz, MD, Dardo Riveros, MD, Luis Palmer, MD, Ider Cerutti, MD, Alfredo Basso, MD, Marta Gelemur, MD, Carlos Cánepa, MD, Gustavo Kusminsky, MD, Marta Zerga, MD

Blood (2005) 106 (11): 4745.

https://doi.org/10.1182/blood.V106.11.4745.4745

Published: 2005

NARROW

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Inducing Iron Deficiency Dramatically Improves Erythropoiesis and Photosensitivity In Congenital Erythropoietic Porphyria (CEP)

Post-Marketing Safety Experience with Edoxaban in Japan for Thromboprophylaxis Following Major Orthopedic Surgery

RCHOP Therapy Overcome Gastric Diffuse Large B Cell Lymphoma without Surgery

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Purging in Vivo and Auto-Transplantation in Patients with Poor Prognosis Lymphoproliferative Disease

Cost Estimates of Managing Grade III and IV Pleural Effusions, Pericardial Effusions, and Non-Variceal Gastrointestinal Hemorrhages in Cancer Patients.

Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus Thalidomide in Refractory Myeloma.

Surgical Complications in Patients Treated with Chemotherapy for Gastric Diffuse Large B Cell Lymphoma.

Anti-Thrombotic Action of DZ-697b, a Novel Anti-Platelet Agent, on Photochemically Induced Thrombosis with Lower Bleeding Risk in Guinea Pigs.

Rituximab - Inmunotherapy Combined with Chemotherapy, CHOP for the Treatment of Patients with Difusse Large B - Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only